During COVID-19 pandemic, inflammatory bowel disease patients were significantly worried about being at a higher risk of getting COVID-19 infection, the effect of their medications on the course of infection and the expected prognosis. This is a retrospective cohort study done in Our Inflammatory bowel disease unit, Tropical Medicine Department, Ain Shams University Hospitals, Cairo, Egypt. We retrospectively reviewed all our patients infected with COVID-19 (13 patients) during the period from March 2020 till mid-September 2020. Thirteen patients in our unit were infected with COVID-19. The mean age of infected patients was 39.92 ± 11.16 years. Most of them were females 11 (84.6%). Most of them had ulcerative colitis (61.5%) and only 38.5% had crohn's disease. Only six patients were admitted to isolation hospital, all of them were ulcerative colitis. The most common presenting symptoms were fever (84.6%), cough (76.9%) and diarrhea (61.5%). Three of ulcerative colitis patients encountered disease exacerbation. All our infected patients had a good prognosis regarding their inflammatory bowel disease and COVID-19 course. COVID-19 infection in inflammatory bowel disease patients may carry a favorable outcome despite the vulnerability of those patients.
| Published in | American Journal of BioScience (Volume 9, Issue 2) |
| DOI | 10.11648/j.ajbio.20210902.13 |
| Page(s) | 47-54 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Ulcerative Colitis, Crohn's Disease, COVID-19, Egypt
| [1] | Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270-3. |
| [2] | Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern [published correction appears in Lancet. 2020 Jan 29]. Lancet 2020; 395: 470-3. |
| [3] | World Health Organization [Internet]. [Cited 2020 Dec 27]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/accessed 27/12/2020 |
| [4] | Beaugerie L, Kirchgesner J. Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019; 17: 370-9. |
| [5] | Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated with Treatment of Inflammatory Bowel Diseases. Gastroenterology 2018; 155: 337-46. |
| [6] | Tezel A, Dökmeci G, Eskiocak M, Umit H, Soylu AR. Epidemiological features of ulcerative colitis in Trakya, Turkey. J Int Med Res 2003; 31: 141-8. |
| [7] | Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The oncologist 2018; 23: 943. |
| [8] | McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis 2020; 7: 105. |
| [9] | Egyptian ministry of health and population. National protocol for management of COVID-19 patients. [Cited 2020 Dec 20]. Available from: http://www.mohp.gov.eg/JobsDetails.aspx?job_id=3061 |
| [10] | Mostafa EF, Metwally A, Hussein SA. Inflammatory bowel diseases prevalence in patients underwent colonoscopy in Zagazig University Hospitals. Afro-Egyptian Journal of Infectious and Endemic Diseases 2018; 8: 81–7. |
| [11] | Eltabbakh MM, Shamkh MAA, Bassuny AN, Abd Alaty WH, Sakr MA, Sherief AF. Inflammatory Bowel Diseases in Egypt During the COVID-19 Pandemic. Inflamm Bowel Dis 2020; 26: 1771-8. |
| [12] | Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020; 115: 766-73. |
| [13] | Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology 2020; 159: 350-7. |
| [14] | Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. [published correction appears in Lancet Gastroenterol Hepatol. 2020 Jul; 5: e6]. Lancet Gastroenterol Hepatol 2020; 5: 426-8. |
| [15] | Fiorino G, Allocca M, Furfaro F, Gilardi D, Zilli A, Radice S, et al. Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan, experience. J Crohns Colitis 2020; 14: 1330-3. |
| [16] | Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin Gastroenterol Hepatol 2020; 18: 2134-5. |
| [17] | Martins-Filho PR, Barreto-Alves JA, Fakhouri R. Potential role for nitazoxanide in treating SARS-CoV-2 infection. Am J Physiol Lung Cell Mol Physiol 2020; 319: 35–6. |
APA Style
Ahmed Fouad Sherief, Mostafa Abd Alfattah Shamkh, Mohamed Amin Sakr, Waleed Hamed Abd Alaty, Ahmed Nagah Bassuny, et al. (2021). Clinical Characteristics of Egyptian Patients with Inflammatory Bowel Diseases Infected with COVID-19: Tertiary Center Experience from Egypt. American Journal of BioScience, 9(2), 47-54. https://doi.org/10.11648/j.ajbio.20210902.13
ACS Style
Ahmed Fouad Sherief; Mostafa Abd Alfattah Shamkh; Mohamed Amin Sakr; Waleed Hamed Abd Alaty; Ahmed Nagah Bassuny, et al. Clinical Characteristics of Egyptian Patients with Inflammatory Bowel Diseases Infected with COVID-19: Tertiary Center Experience from Egypt. Am. J. BioScience 2021, 9(2), 47-54. doi: 10.11648/j.ajbio.20210902.13
AMA Style
Ahmed Fouad Sherief, Mostafa Abd Alfattah Shamkh, Mohamed Amin Sakr, Waleed Hamed Abd Alaty, Ahmed Nagah Bassuny, et al. Clinical Characteristics of Egyptian Patients with Inflammatory Bowel Diseases Infected with COVID-19: Tertiary Center Experience from Egypt. Am J BioScience. 2021;9(2):47-54. doi: 10.11648/j.ajbio.20210902.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajbio.20210902.13,
author = {Ahmed Fouad Sherief and Mostafa Abd Alfattah Shamkh and Mohamed Amin Sakr and Waleed Hamed Abd Alaty and Ahmed Nagah Bassuny and Ibrahim Abdelhakim Ibrahim and Safaa Ragab Askar and Shimaa Yousef Kamel and Heba Rashad and Mohamed Mahmoud Eltabbakh},
title = {Clinical Characteristics of Egyptian Patients with Inflammatory Bowel Diseases Infected with COVID-19: Tertiary Center Experience from Egypt},
journal = {American Journal of BioScience},
volume = {9},
number = {2},
pages = {47-54},
doi = {10.11648/j.ajbio.20210902.13},
url = {https://doi.org/10.11648/j.ajbio.20210902.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbio.20210902.13},
abstract = {During COVID-19 pandemic, inflammatory bowel disease patients were significantly worried about being at a higher risk of getting COVID-19 infection, the effect of their medications on the course of infection and the expected prognosis. This is a retrospective cohort study done in Our Inflammatory bowel disease unit, Tropical Medicine Department, Ain Shams University Hospitals, Cairo, Egypt. We retrospectively reviewed all our patients infected with COVID-19 (13 patients) during the period from March 2020 till mid-September 2020. Thirteen patients in our unit were infected with COVID-19. The mean age of infected patients was 39.92 ± 11.16 years. Most of them were females 11 (84.6%). Most of them had ulcerative colitis (61.5%) and only 38.5% had crohn's disease. Only six patients were admitted to isolation hospital, all of them were ulcerative colitis. The most common presenting symptoms were fever (84.6%), cough (76.9%) and diarrhea (61.5%). Three of ulcerative colitis patients encountered disease exacerbation. All our infected patients had a good prognosis regarding their inflammatory bowel disease and COVID-19 course. COVID-19 infection in inflammatory bowel disease patients may carry a favorable outcome despite the vulnerability of those patients.},
year = {2021}
}
TY - JOUR T1 - Clinical Characteristics of Egyptian Patients with Inflammatory Bowel Diseases Infected with COVID-19: Tertiary Center Experience from Egypt AU - Ahmed Fouad Sherief AU - Mostafa Abd Alfattah Shamkh AU - Mohamed Amin Sakr AU - Waleed Hamed Abd Alaty AU - Ahmed Nagah Bassuny AU - Ibrahim Abdelhakim Ibrahim AU - Safaa Ragab Askar AU - Shimaa Yousef Kamel AU - Heba Rashad AU - Mohamed Mahmoud Eltabbakh Y1 - 2021/03/30 PY - 2021 N1 - https://doi.org/10.11648/j.ajbio.20210902.13 DO - 10.11648/j.ajbio.20210902.13 T2 - American Journal of BioScience JF - American Journal of BioScience JO - American Journal of BioScience SP - 47 EP - 54 PB - Science Publishing Group SN - 2330-0167 UR - https://doi.org/10.11648/j.ajbio.20210902.13 AB - During COVID-19 pandemic, inflammatory bowel disease patients were significantly worried about being at a higher risk of getting COVID-19 infection, the effect of their medications on the course of infection and the expected prognosis. This is a retrospective cohort study done in Our Inflammatory bowel disease unit, Tropical Medicine Department, Ain Shams University Hospitals, Cairo, Egypt. We retrospectively reviewed all our patients infected with COVID-19 (13 patients) during the period from March 2020 till mid-September 2020. Thirteen patients in our unit were infected with COVID-19. The mean age of infected patients was 39.92 ± 11.16 years. Most of them were females 11 (84.6%). Most of them had ulcerative colitis (61.5%) and only 38.5% had crohn's disease. Only six patients were admitted to isolation hospital, all of them were ulcerative colitis. The most common presenting symptoms were fever (84.6%), cough (76.9%) and diarrhea (61.5%). Three of ulcerative colitis patients encountered disease exacerbation. All our infected patients had a good prognosis regarding their inflammatory bowel disease and COVID-19 course. COVID-19 infection in inflammatory bowel disease patients may carry a favorable outcome despite the vulnerability of those patients. VL - 9 IS - 2 ER -
Email: